NCT05023278View on ClinicalTrials.gov

The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

March 31, 2025

Conditions
Acute PainChronic PainKnee Pain ChronicNeuropathic Pain
Interventions
DRUG

Venlafaxine 37.5 MG

venlafaxine 37.5mg daily for 7 consecutive days.

DRUG

Placebo

placebo filled pill daily for 7 consecutive days.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

Orthopedic Research and Education Foundation

OTHER

lead

University of California, San Francisco

OTHER